about
Transjugular intrahepatic portosystemic shunts for hepatorenal syndromeSelective vasopressin type 2 receptor antagonist for patients with cirrhosisAntibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleedingBariatric surgery for non-alcoholic steatohepatitis in obese patientsAntibiotics for spontaneous bacterial peritonitis in cirrhotic patientsImage-guided percutaneous procedure plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscessBariatric surgery for non-alcoholic steatohepatitis in obese patientsRole of bioactive fatty acids in nonalcoholic fatty liver diseaseMitochondrial Molecular Pathophysiology of Nonalcoholic Fatty Liver Disease: A Proteomics ApproachGranulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysisSerum leptin levels and insulin resistance are associated with gallstone disease in overweight subjects.Metabolic syndrome as a risk factor for gallstone disease.Low serum levels of ghrelin are associated with gallstone disease.Bilirubin alone as a biomarker for short-term mortality in acute-on-chronic liver failure: an important prognostic indicator.Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.Endoscopic treatment of high-risk bleeding ulcers: success, rebleeding and mortality.Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.Clinical heterogeneity in autoimmune acute liver failureEffect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease.PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis.Upper gastrointestinal dieulafoy's lesions and endoscopie treatment: first report from a mexican centre.Clinical impact of indirect markers of renal function in elderly patients with hip fracture.Adiponectin as a protective factor in hepatic steatosis.The role of dietary fats in the pathogenesis of gallstones.Nuclear receptors in nonalcoholic Fatty liver diseaseThe endocannabinoid system in chronic liver disease.A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy.Non-alcoholic fatty-liver disease in pediatric populations.The molecular basis of susceptibility to infection in liver cirrhosis.Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis.Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico.Diagnostic accuracy of nodular gastritis for H. pylori infection.Acute-on-chronic liver failure: a review.Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure.Hepatic manifestations of metabolic syndrome.The prevalence of nonalcoholic fatty liver disease in the Americas.Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis.Latin American Association for the Study of the Liver recommendations on treatment of hepatitis C.Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis.The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease.
P50
Q24198269-B4B72028-34CF-43C1-BA35-7F83FFAA3284Q24234739-FBADFE82-8777-43BB-A64A-C80FBD8985EFQ24235526-7E044AC8-B51E-42B9-9DED-5B6C1B641213Q24240455-9D2C746B-6029-442D-BA30-8DC2ECC9F3A3Q24240955-0B7B1E37-68EF-4887-8F70-7951957684B9Q24241178-1001C1B6-913E-4EDC-9FE1-59C73D421C08Q24242858-0B4EA28C-3480-4BDE-8E66-F20191B1F097Q26739904-BA9B9B01-C696-4F29-8487-7F24A8418896Q26753043-30D72813-0830-4A38-A294-D128AA5451EDQ26800374-8035191D-7A82-4797-BCC8-7412AAD4B2C3Q30411805-85D4F6C5-2546-46D0-B812-1F24678EEA2EQ30420193-DA9E59BD-C5FA-4CEF-8C26-57D122AEAD26Q30433017-63E4509B-0554-45B8-8055-A3115A7A7E05Q30457278-BB943692-05F6-4C80-931E-CCE707784635Q33268183-20E033D0-FA5A-4326-B7D5-343C1F31CC94Q33327531-8BC1845A-6958-4503-A434-A5D92930542EQ33509626-3CC6D8ED-1317-4403-AFAD-36F3192D39A6Q34112226-A85177FA-7ADE-43B2-B087-2D522C247FD9Q34180476-AF116533-4A1D-4B30-AFE3-9AFDB08F1592Q34406501-B5C8593E-D5F3-4D7F-94BD-69B3342B0DDEQ34408913-18875A3E-D00F-4620-B8D5-ADEC643184ABQ34418572-5221D8A3-EF41-4BA5-A927-DECA98717593Q35011045-CABE46F9-022E-4599-A28C-2C65F928E6B4Q35109598-B6D5D941-DFB3-43B6-B630-C3FBD72B6D43Q35609154-C0C1A358-EACD-4FE6-8B06-38678686F562Q36375971-165261A6-08AD-4DFB-8E0C-BBEF60ADB80AQ36945543-7185C621-622D-4156-BF58-6C54D08D8F3DQ37021138-9BB1A814-19F1-4C6F-8986-B0E0D5B551A1Q37066027-ABF31C3B-D8CB-4084-A60B-21CF0BD57AE4Q37336398-1BB7C225-CF86-43F5-BE74-7841E93DD5E9Q37511212-3D4A5202-142F-45D5-A84F-134898E72E90Q37527849-85C12C48-BE0A-47BC-88F3-1BB8DF59A0FDQ37729728-C4BCFA05-B37C-41ED-A5C2-B9C7C31B92B2Q37974189-A2DCFBD9-77C1-4F90-B4D3-D8108710C755Q38087575-9E71DBB5-E9EE-40A9-9133-1FE0D4709FEAQ38189526-72CB2032-6345-4A55-A7C7-2B405010CCA9Q38220070-811F1A42-83FE-46AC-948C-8CC6F30180E0Q38245830-82EA8A36-C8BB-493C-B318-2E90C7887F71Q38299183-1B8A22A6-448F-4BA4-90E9-7D01666143FAQ38544156-DD588457-A4A8-4DF3-9479-AB61ADEC9AEE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
name
Norberto Carlos Chávez-Tapia
@ast
Norberto Carlos Chávez-Tapia
@en
Norberto Carlos Chávez-Tapia
@sl
type
label
Norberto Carlos Chávez-Tapia
@ast
Norberto Carlos Chávez-Tapia
@en
Norberto Carlos Chávez-Tapia
@sl
altLabel
Norberto C Chavez-Tapia
@en
Norberto C Chávez-Tapia
@en
Norberto C. Chavez-Tapia
@en
Norberto C. Chávez-Tapia
@en
Norberto Carlos Chavez-Tapia
@en
Norberto Chavez-Tapia
@en
Norberto Chávez-Tapia
@en
prefLabel
Norberto Carlos Chávez-Tapia
@ast
Norberto Carlos Chávez-Tapia
@en
Norberto Carlos Chávez-Tapia
@sl